Rchr
J-GLOBAL ID：201801006721958392   Update date: Sep. 12, 2024

Watanabe Satoshi

ワタナベ サトシ | Watanabe Satoshi
Affiliation and department：
Niigata University Graduate School of Medical and Dental Sciences

About Niigata University Graduate School of Medical and Dental Sciences


Research field  (1)： Tumor diagnostics and therapeutics
Research keywords  (3)： 腫瘍免疫 ,  腫瘍 ,  呼吸器
Research theme for competitive and other funds  (6)：
  • 2019 - 2023 メガリンを標的とした薬剤性腎障害治療戦略の開発
  • 2015 - 2018 Novel antitumor immunotherapy via immune reconstitution after chemotherapy for advanced lung cancer
  • 2012 - 2015 Search of the effect predictive factor in molecules target therapy for lung cancer
  • 2012 - 2015 Novel tumor immunotharapy for advanced lung cancer using homeostatic reconstitution of antitumor immunity
  • 2009 - 2011 Development of system to predict postoperative recurrence of lung cancer/order-made treatment using peripheral blood circukationg tumor cell
Show all
Papers (224)：
  • Motohiko Yamazaki, Satoshi Watanabe, Masaki Tominaga, Takuya Yagi, Yukari Goto, Naohiro Yanagimura, Masashi Arita, Aya Ohtsubo, Tomohiro Tanaka, Koichiro Nozaki, et al. 18F-FDG-PET/CT Uptake by Noncancerous Lung as a Predictor of Interstitial Lung Disease Induced by Immune Checkpoint Inhibitors. Academic radiology. 2024
  • Tetsuhiko Asao, Takehito Shukuya, Kohei Uemura, Rui Kitadai, Gaku Yamamoto, Atsuto Mouri, Meiyo Tamaoka, Ryosuke Imai, Yoko Tsukita, Kazutoshi Isobe, et al. Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047). Lung cancer (Amsterdam, Netherlands). 2024. 194. 107894-107894
  • Naohiro Yanagimura, Satoshi Watanabe, Toshiaki Kikuchi. Combined PARP and PD-L1 inhibition: a promising treatment option for relapsed small-cell lung cancer. Journal of thoracic disease. 2024. 16. 6. 4075-4078
  • Satoshi Watanabe, Toshiaki Kikuchi. Does Autoimmune Response Against Surfactant Protein Cause Interstitial Lung Disease?. American journal of respiratory and critical care medicine. 2024
  • 有波 純, 柳村 尚寛, 関谷 友樹, 有田 将史, 大坪 亜矢, 田中 知宏, 野嵜 幸一郎, 才田 優, 近藤 利恵, 渡部 聡, et al. 当院におけるMET遺伝子変異陽性非小細胞肺癌に対するテポチニブ療法に関する後方視的検討. 肺癌. 2024. 64. 3. 257-257
ｍore...
MISC (145)：
  • 桝田 尚明, 渡部 聡, 菖野 邦浩, 鈴木 遼, 関谷 友樹, 大坪 亜矢, 田中 知宏, 野嵜 幸一郎, 才田 優, 近藤 利恵, et al. 非小細胞肺癌のサルコペニア患者に対する免疫療法の効果に関わる網羅的蛋白解析(Comprehensive protein analysis of the effect of immunotherapy in non-small cell lung cancer patients with sarcopenia). 日本癌学会総会記事. 2023. 82回. 848-848
  • 小山建一, 山田忠明, 後藤康洋, 木村英晴, 湊浩一, 山口博之, 本田健, 渡部聡, 清見文明, 内野順治, et al. A phase 2 trial of durvalumab treatment in NSCLC patients ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT Study). 日本呼吸器学会誌(Web). 2023. 12
  • 森本健司, 山田忠明, 平井聡一, 片山勇輝, 國政啓, 佐々木高明, 西田真, 渡部聡, 塩津伸介, 西岡直哉, et al. AXLシグナル活性化によるKRAS-G12C阻害薬の初期治療抵抗性機構の解明と治療法開発. 日本肺癌学会学術集会号. 2023. 64th (CD-ROM)
  • 大坪 亜矢, 後藤 優佳, 鈴木 遼, 庄子 聡, 島 賢治郎, 田中 知宏, 野嵜 幸一郎, 才田 優, 木村 陽介, 穂苅 諭, et al. 分子標的薬を安全に使用できたEGFR遺伝子変異陽性肺癌合併妊娠の一例. 肺癌. 2022. 62. 6. 725-725
  • 渡部聡, 山田忠明, 吉村彰紘, 福田滉仁, 福田滉仁, 大熊裕介, 大熊裕介, 西岡直哉, 竹田隆之, 千原佑介, et al. Treatment with osimertinib for untreated EGFR mutated non-small cell lung cancer patients: a multicenter prospective observational study in Japanese cohort. 日本呼吸器学会誌(Web). 2022. 11
ｍore...
Professional career (1)：
  • 医学博士 (新潟大学)
Association Membership(s) (8)：
Japanese society of medical oncology ,  International association for the study of lung cancer ,  American association for cancer research ,  THE JAPANESE CANCER ASSOCIATION ,  THE JAPAN SOCIETY FOR RESPIRATORY ENDOSCOPY ,  THE JAPAN LUNG CANCER SOCIETY ,  THE JAPANESE RESPIRATORY SOCIETY ,  THE JAPANESE SOCIETY OF INTERNAL MEDICINE
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM